Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/sciences-de-la-vie/ion-channels-as-therapeutic-targets-part-b/descriptif_3776257
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3776257

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Ion Channels as Therapeutic Targets, Part B

Langue : Anglais

Directeur de Collection : Donev Rossen

Couverture de l’ouvrage Ion Channels as Therapeutic Targets, Part B

This volume is the second part of the thematic on Ion Channels as Therapeutic Targets.

The popular Advances in Protein Chemistry and Structural Biology series, an essential resource for protein chemists, brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.

1. Role of Hemichannels in CNS Inflammation and the Inflammasome Pathway Yuri Kim, Joanne O. Davidson, Katherine C. Gunn, Anthony R. Phillips, Colin R. Green and Alistair J. Gunn 2. P2X7 Receptors as a Therapeutic Target Elena De Marchi, Elisa Orioli, Diego Dal Ben and Elena Adinolfi 3. Polymodal Transient Receptor Potential Vanilloid Type 1 (TRPV1) Nocisensor: Structure, Modulators, and Therapeutic Applications Minghua Cui, Vijayakumar Gosu, Shaherin Basith, Sunhye Hong and Sun Choi 4. TRPM8 ion Channels as Potential Cancer Biomarker and Target in Pancreatic Cancer Nelson S. Yee 5. Ion Channels In The Eye: Involvement In Ocular Pathologies Jonathan P Giblin, Nuria Comes, Olaf Strauss and Xavier Gasull 6. Calcium-Activated Potassium Channels: Potential Target for Cardiovascular Diseases De-Li Dong, Yun-Long Bai and Ben-Zhi Cai 7. The Modulation of Potassium Channels in the Smooth Muscle as a Therapeutic Strategy for Disorders of the Gastrointestinal Tract Diego Currò 8. Targeting the Channel Activity of Viroporins Janet To, Wahyu Surya and Jaume Torres 9. Contribution of Automated Technologies to Ion Channel Drug Discovery Arturo Picones, Arlet Loza-Huerta, Pedro Segura-Chama and Cesar O. Lara Figueroa

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
  • Provides cutting-edge developments in protein chemistry and structural biology
  • Discusses the use of ion channels as therapeutic targets
  • Chapters are written by authorities in their field
  • Targeted to a wide audience of researchers, specialists, and students

Date de parution :

Ouvrage de 466 p.

15x22.8 cm

Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).

146,54 €

Ajouter au panier

Thèmes d’Ion Channels as Therapeutic Targets, Part B :